UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003089
Receipt number R000002254
Scientific Title Effects of beraprost sodium on improvement of insulin resistance in patients with type 2 diabetes and peripheral arterial disease
Date of disclosure of the study information 2010/01/25
Last modified on 2014/04/24 12:04:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of beraprost sodium on improvement of insulin resistance in patients with type 2 diabetes and peripheral arterial disease

Acronym

Effects of beraprost sodium on improvement of insulin resistance in patients with type 2 diabetes and peripheral arterial disease

Scientific Title

Effects of beraprost sodium on improvement of insulin resistance in patients with type 2 diabetes and peripheral arterial disease

Scientific Title:Acronym

Effects of beraprost sodium on improvement of insulin resistance in patients with type 2 diabetes and peripheral arterial disease

Region

Japan


Condition

Condition

Patients with type 2 diabetes and peripheral arterial disease

Classification by specialty

Cardiology Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effect of beraprost sodium on improvement of insulin resistance

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Glucose infusion rate on euglycemic hyperinsulinemic clamp (0, 12 weeks)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral beraprost sodium for 12 weeks for patients with type 2 diabetes and peripheral arterial disease

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Type 2 diabetes
HbA1c<8%
BMI>=25 or "Male Waist>=85cm or Female Waist>=90cm"
with untreated peripheral arterial disease

Key exclusion criteria

- Patients with bleeding tendancy
- Patients with severe renal dysfunction
- Patients with liver dysfunction
- Patients with a past hystory of drug hypersensitivity
- Pregnant women or women with breast-feeding
- Patients who took prostaglandin derivatives within 3 months

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Naoto Kubota

Organization

Graduate School of Medicine, University of Tokyo

Division name

Department of Metabolic Diseases

Zip code


Address

7-3-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-5800-8818

Email

nkubota-tky@umin.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hisayuki Katsuyama

Organization

Graduate School of Medicine, University of Tokyo

Division name

Department of Metabolic Diseases

Zip code


Address

Hongo 7-3-1, Bunkyo, Tokyo, Japan

TEL

03-5800-8818

Homepage URL


Email

katsuyama-hs@umin.ac.jp


Sponsor or person

Institute

Graduate School of Medicine, University of Tokyo
Department of Metabolic Diseases

Institute

Department

Personal name



Funding Source

Organization

Ministry of Education, Culture, Sports, Science & Technology

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京大学医学部附属病院


Other administrative information

Date of disclosure of the study information

2010 Year 01 Month 25 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://link.springer.com/article/10.1007/s13340-014-0169-8

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 03 Month 26 Day

Date of IRB


Anticipated trial start date

2009 Year 04 Month 01 Day

Last follow-up date

2011 Year 06 Month 08 Day

Date of closure to data entry

2012 Year 03 Month 31 Day

Date trial data considered complete

2012 Year 03 Month 31 Day

Date analysis concluded

2013 Year 08 Month 31 Day


Other

Other related information



Management information

Registered date

2010 Year 01 Month 25 Day

Last modified on

2014 Year 04 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002254


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name